Natriuretic peptide analogues with distinct vasodilatory or renal activity : integrated effects in health and experimental heart failure
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissionsoup.com..
AIMS: Management of acute decompensated heart failure (ADHF) requires disparate treatments depending on the state of systemic/peripheral perfusion and the presence/absence of expanded body-fluid volumes. There is an unmet need for therapeutics that differentially treat each aspect. Atrial natriuretic peptide (ANP) plays an important role in blood pressure and volume regulation. We investigate for the first time the integrated haemodynamic, endocrine and renal effects of human ANP analogues, modified for exclusive vasodilatory (ANP-DRD) or diuretic (ANP-DGD) activities, in normal health and experimental ADHF.
METHODS AND RESULTS: We compared the effects of incremental infusions of ANP analogues ANP-DRD and ANP-DGD with native ANP, in normal (n = 8) and ADHF (n = 8) sheep. ANP-DRD administration increased plasma cyclic guanosine monophosphate (cGMP) in association with dose-dependent reductions in arterial pressure in normal and heart failure (HF) sheep similarly to ANP responses. In contrast to ANP, which in HF produced a diuresis/natriuresis, this analogue was without significant renal effect. Conversely, ANP-DGD induced marked stepwise increases in urinary cGMP, urine volume, and sodium excretion in HF comparable to ANP, but without accompanying vasodilatory effects. All peptides increased packed cell volume relative to control in both states, and in HF, decreased left atrial pressure. In response to ANP-DRD-induced blood pressure reductions, plasma renin activity rose compared to control only during the high dose in normals, and not at all in HF-suggesting relative renin inhibition, with no increase in aldosterone in either state, whereas renin and aldosterone were both significantly reduced by ANP-DGD in HF.
CONCLUSION: These ANP analogues exhibit distinct vasodilatory (ANP-DRD) and diuretic/natriuretic (ANP-DGD) activities, and therefore have the potential to provide precision therapy for ADHF patients with differing pathophysiological derangement of pressure-volume homeostasis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:117 |
|---|---|
| Enthalten in: |
Cardiovascular research - 117(2021), 2 vom: 21. Jan., Seite 508-519 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rademaker, Miriam T [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.12.2021 Date Revised 14.12.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cvr/cvaa052 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307556662 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307556662 | ||
| 003 | DE-627 | ||
| 005 | 20231225125826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cvr/cvaa052 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1025.xml |
| 035 | |a (DE-627)NLM307556662 | ||
| 035 | |a (NLM)32167565 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rademaker, Miriam T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Natriuretic peptide analogues with distinct vasodilatory or renal activity |b integrated effects in health and experimental heart failure |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a AIMS: Management of acute decompensated heart failure (ADHF) requires disparate treatments depending on the state of systemic/peripheral perfusion and the presence/absence of expanded body-fluid volumes. There is an unmet need for therapeutics that differentially treat each aspect. Atrial natriuretic peptide (ANP) plays an important role in blood pressure and volume regulation. We investigate for the first time the integrated haemodynamic, endocrine and renal effects of human ANP analogues, modified for exclusive vasodilatory (ANP-DRD) or diuretic (ANP-DGD) activities, in normal health and experimental ADHF | ||
| 520 | |a METHODS AND RESULTS: We compared the effects of incremental infusions of ANP analogues ANP-DRD and ANP-DGD with native ANP, in normal (n = 8) and ADHF (n = 8) sheep. ANP-DRD administration increased plasma cyclic guanosine monophosphate (cGMP) in association with dose-dependent reductions in arterial pressure in normal and heart failure (HF) sheep similarly to ANP responses. In contrast to ANP, which in HF produced a diuresis/natriuresis, this analogue was without significant renal effect. Conversely, ANP-DGD induced marked stepwise increases in urinary cGMP, urine volume, and sodium excretion in HF comparable to ANP, but without accompanying vasodilatory effects. All peptides increased packed cell volume relative to control in both states, and in HF, decreased left atrial pressure. In response to ANP-DRD-induced blood pressure reductions, plasma renin activity rose compared to control only during the high dose in normals, and not at all in HF-suggesting relative renin inhibition, with no increase in aldosterone in either state, whereas renin and aldosterone were both significantly reduced by ANP-DGD in HF | ||
| 520 | |a CONCLUSION: These ANP analogues exhibit distinct vasodilatory (ANP-DRD) and diuretic/natriuretic (ANP-DGD) activities, and therefore have the potential to provide precision therapy for ADHF patients with differing pathophysiological derangement of pressure-volume homeostasis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Acute decompensated heart failure | |
| 650 | 4 | |a Diuresis | |
| 650 | 4 | |a Vasodilation | |
| 650 | 4 | |a Atrial natriuretic peptide analogues | |
| 650 | 7 | |a Diuretics |2 NLM | |
| 650 | 7 | |a Endothelin-1 |2 NLM | |
| 650 | 7 | |a Vasodilator Agents |2 NLM | |
| 650 | 7 | |a Natriuretic Peptide, Brain |2 NLM | |
| 650 | 7 | |a 114471-18-0 |2 NLM | |
| 650 | 7 | |a Aldosterone |2 NLM | |
| 650 | 7 | |a 4964P6T9RB |2 NLM | |
| 650 | 7 | |a Atrial Natriuretic Factor |2 NLM | |
| 650 | 7 | |a 85637-73-6 |2 NLM | |
| 650 | 7 | |a Renin |2 NLM | |
| 650 | 7 | |a EC 3.4.23.15 |2 NLM | |
| 650 | 7 | |a Cyclic GMP |2 NLM | |
| 650 | 7 | |a H2D2X058MU |2 NLM | |
| 700 | 1 | |a Scott, Nicola J A |e verfasserin |4 aut | |
| 700 | 1 | |a Koh, Cho Yeow |e verfasserin |4 aut | |
| 700 | 1 | |a Kini, R Manjunatha |e verfasserin |4 aut | |
| 700 | 1 | |a Richards, A Mark |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular research |d 1967 |g 117(2021), 2 vom: 21. Jan., Seite 508-519 |w (DE-627)NLM000080209 |x 1755-3245 |7 nnns |
| 773 | 1 | 8 | |g volume:117 |g year:2021 |g number:2 |g day:21 |g month:01 |g pages:508-519 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cvr/cvaa052 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 117 |j 2021 |e 2 |b 21 |c 01 |h 508-519 | ||